Long-term synaptic potentiation

Across TCGA pan-cancer cohorts, RNA activity of the Long-term synaptic potentiation pathway differs between tumor and matched normal tissue in 9 of the 18 cancer types tested.

The strongest signal is observed in breast invasive carcinoma (BRCA), where pathway activity is lower in tumor tissue than in matched normal tissue. In most cancer types, this pathway shows higher activity in tumors, although a few cancer types, such as BRCA and LUAD, show the opposite pattern, with lower activity in tumor tissue.

BRCA, LUAD, and LUSC show the most reproducible tumor–normal differences in pathway activity.

Tumor vs normal pathway activity by lineage

Ranked by sampling consensus. Activity change represents the tumor-versus-normal difference in pathway activity on a log₂ scale. Positive values indicate higher pathway activity in tumor tissue. The reported p-values are derived from the corresponding differential activity tests.

Lineage	Gender	Stage	Activity change	p	Sampling consensus
BRCA	Female	All	−0.038	<.001	6	view →
LUAD	All	All	−0.013	<.001	6	view →
LUSC	All	All	−0.014	<.001	5	view →
KIRC	All	All	−0.010	.003	5	view →
UCEC	All	II,III,IV	−0.029	.022	4	view →
LIHC	All	All	−0.012	<.001	3	view →
PRAD	All	All	−0.014	<.001	2	view →
READ	All	All	−0.026	.018	1	view →
HNSC	Female	IV	−0.016	.014	1	view →

Pink = more active in tumor, green = less active in tumor. Showing the 9 strongest of 9 lineages.

GO:0060291–BRCA

Open the BRCA breakdown →